QR code

Longitudinal Circulating Tumor DNA–Guided Resistance Analysis During Second-Line Osimertinib Treatment

Introduction: In osimertinib-treated EGFR mutation (EGFRm)–positive NSCLC, resistance inevitably occurs. Early resistance mechanism (RM) detection by circulating tumor DNA (ctDNA) in plasma and consecutive targeted treatment may delay progressive disease (PD). In this multicenter prospective study,...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: J.W. Tijmen van der Wel, MD, Merel Jebbink, MD, Vincent van der Noort, PhD, Ferry Lalezari, MD, PhD, Daan van den Broek, PhD, Gerrina Ruiter, MD, PhD, Jacobus A. Burgers, MD, PhD, Paul Baas, MD, PhD, Anne S.R. van Lindert, MD, Eva E. van der Wall, MD, Lisanne E.A. Kastelijn, MD, PhD, Marrit Vermeulen, BSc, Linda J.W. Bosch, PhD, Kim Monkhorst, MD, PhD, Mirjam C. Boelens, PhD, Egbert F. Smit, MD, PhD, Adrianus J. de Langen, MD, PhD
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2025-09-01
Reeks:JTO Clinical and Research Reports
Onderwerpen:
EGFR
NSCLC
Osimertinib
Resistance
ctDNA
Online toegang:http://www.sciencedirect.com/science/article/pii/S2666364325000700
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items